AnnCatherine M. Downing

Author

Eli Lilly (United States)

Also Known As

A M Downing, A.M. Downing, AnnCatherine M Downing, AnnCatherine M. Downing

Publications

855

Citations

H-Index

Concepts

All Affiliations

Eli Lilly (United States)AstraZeneca (United States)

About

AnnCatherine M. Downing is an author at Eli Lilly (United States) specializing in medicine, neuroscience, and social sciences.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	439
2	Neuroscience	3	3	439
3	Social Sciences	2	2	78
4	Pharmacology	2	2	78
5	Neurology	1	1	22

AnnCatherine M. Downing

Publications

822

Citations

H-Index

Page 1

	Year	Citations
Genomewide association for schizophrenia in the CATIE study: results of stage 1 Patrick F. Sullivan, D. Y. Lin, J.‐W. Tzeng, Molecular Psychiatry Genome-wide Association StudyPsychiatryGeneticsGenomewide AssociationGenetic Epidemiology	2008	361
Efficacy and Safety of Lanabecestat for Treatment of Early and Mild Alzheimer Disease Alette M. Wessels, Pierre N. Tariot, Jennifer A. Zimmer, JAMA Neurology	2019	191
A double-blind, placebo-controlled comparator study of LY2140023 monohydrate in patients with schizophrenia AnnCatherine M. Downing, Bruce J. Kinon, Brian A. Millen, BMC Psychiatry	2014	113
A Haplotype of the Norepinephrine Transporter (Net) Gene Slc6a2 is Associated with Clinical Response to Atomoxetine in Attention-Deficit Hyperactivity Disorder (ADHD) Nicolás Ramoz, Claudette Boni, AnnCatherine M. Downing, Neuropsychopharmacology AdhdPsychiatryAttention-deficit Hyperactivity DisorderMedicineNeurotransmitter	2009	56
Retrospective assessment of patient characteristics and healthcare costs prior to a diagnosis of Alzheimer’s disease in an administrative claims database Radhika Nair, Virginia S. Haynes, Mir S. Siadaty, BMC Geriatrics	2018	38
Lanabecestat: Neuroimaging results in early symptomatic Alzheimer's disease Jennifer A. Zimmer, Sergey Shcherbinin, Michael D. Devous, Alzheimer s & Dementia Translational Research & Clinical Interventions	2021	25
Development Review of the BACE1 Inhibitor Lanabecestat (AZD3293/LY3314814). John R. Sims, Katherine J. Selzler, AnnCatherine M. Downing, PubMed Human Beta-site AmyloidPharmacotherapySocial SciencesMolecular PharmacologyNeurobiology Of Disease	2017	22
Identifying Pharmacodynamic Protein Markers of Centrally Active Drugs in Humans: A Pilot Study in a Novel Clinical Model Sandeep T. Patil, Richard E. Higgs, J Brandt, Journal of Proteome Research	2007	16

Page 1